This study examined the incidence of hyperamylasaemia, in the absence of other plausible causes of pancreatic dysfunction, in intensive care unit (ICU) patients who received propofol.
Propofol is a sedative-hypnotic agent that has been used for induction of general anaesthesia and for long-term sedation in intensive care units (ICU) for more than 10 years. It is a lipid-based, global central nervous system depressant, with a rapid onset of sedation (within 40 seconds), a dose-related hypnotic effect and a quick and smooth recovery profile. These characteristics have made propofol a favoured sedative agent in the ICU setting where it is available as 1% and 2% solutions in which 1 ml propofol 1% contains 0.1 g lipid.
In the early 1990s, several case reports suggested an association between sedation with high-dose propofol (>4 mg/kg/h), myocardial failure and death in children with respiratory tract infection 1 .
Later reports have suggested a similar propofolinfusion syndrome, consisting of cardiac failure, rhabdomyolysis, severe metabolic acidosis and renal failure, in critically ill adults receiving long-term (>48 h), high-dose (>5 mg/kg/h) infusions, particularly patients with acute neurological or inflammatory illness [1] [2] [3] [4] .
Recently propofol has been implicated as a cause of acute pancreatitis in a series of case reports [5] [6] [7] [8] [9] [10] [11] [12] . The aim of this prospective study was to estimate the incidence of hyperamylasaemia, as a marker of pancreatic complications, in patients who receive propofol in a general ICU.
MATERIALS AND METHODS
The study was reviewed and approved by the Human Study Committee of our institution. Given the nature of the study, the need for informed consent was waived. We studied 172 consecutively admitted patients in a 28-bed University ICU, who stayed for more than 24 hours. These patients were prospectively evaluated from August to December 2004. We initially excluded 86 patients: those with elevated serum amylase levels at admission, those with a diagnosis compatible with hyperamylasaemia (pancreatic disease, abdominal trauma and/or surgery, aneurysmal disease etc) and those with abnormal renal or liver function defined as a Sequential Organ Failure Assessment score (SOFA) >0 in the respective categories. Another 42 patients were subsequently excluded from the study because during their ICU stay they received one or more medications known to raise serum amylase levels, such as aspirin, codeine, valproate, ranitidine, metronidazole and metoclopramide.
Blood samples for biochemical analysis were drawn from the patients every morning and every time that the attending physicians judged it was appropriate to do so. Serum amylase was serially assessed. The blood samples were processed in our hospital's laboratories as usual. All patients who developed hyperamylasaemia during their period of ICU stay received abdominal ultrasound scans by ICU-associated sonographers, which is standard practice in our ICU, in order to exclude abdominal pathology. We have considered 'propofolinduced hyperamylasaemia' a serum amylase level ≥125 IU/l, measured on at least two consecutive days, during or shortly after a course of continuous propofol administration for sedation and for which no alternative diagnosis could be found.
Results from the group of patients that received propofol were compared with results from the group that did not receive propofol using Fisher's exact test to test the association of propofol exposure with the development of hyperamylasaemia.
RESULTS
A total of 44 patients met the criteria of the study. In 30 of these, a continuous infusion of propofol for sedation was used (maximal dose 45 μg/kg/min). The 14 remaining patients did not receive propofol. The diagnoses and baseline characteristics of both groups are shown in Table 1 .
Of the 30 patients who received propofol during the study period, 16 (53%) developed increased levels of serum amylase (125 to 466 IU/l) after two to nine days of continuous infusion. Liver function assessed by blood transaminase levels, and kidney function assessed by blood urea levels and estimated creatinine clearance remained normal throughout the observation period. Of the 14 remaining patients who did not receive propofol, only two (14%) developed transient hyperamylasaemia.
In no case could an adequate explanation for the rise of serum amylase levels be discerned by the work-up that the attending physicians performed. In addition, serum amylase levels in the propofol-receiving patients invariably returned to normal values two to four days after the drug was discontinued. The incidence of hyperamylasaemia was found to be significantly higher in the propofol-infused patients with Fisher's exact test (P=0.021), yielding an odds ratio of 6.86 (95% CI: 1.30 to 36.06).
DISCUSSION
To date there is a certain scarcity of data regarding the possible relationship between propofol and acute pancreatitis. The notion of propofol-induced pancreatic damage seems to be gaining ground in the minds of physicians, though the main body of evidence consists of only a few Head trauma (not facial) 1 0
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Days of ICU stay (median and range) case reports and case series 2,5,6,8,10-12 . Two randomised clinical trials that have been conducted to this day have produced conflicting results 9, 19 . Furthermore, they refer to surgical patients who received propofol for relatively brief periods of time. To our knowledge, this is the only prospective study comparing consecutively admitted patients who received propofol for more than a few hours with patients who did not receive propofol, in order to evaluate its effects on pancreatic function. We evaluated amylasaemia because serum amylase has been the mainstay and remains a standard, easily obtained and cost-effective laboratory examination in the evaluation of pancreatic disease. Serum amylase levels increase in 12 to 24 hours in acute pancreatitis and gradually fall back towards normal over the next three to five days.
Our results show an association of propofol with the development of hyperamylasaemia in patients receiving a propofol infusion, since 16 (53%) out of 30 patients that received propofol developed hyperamylasaemia in contrast to two patients only (14%) out of 14 that did not receive propofol. This is in agreement with other reports that have shown a possible link between the use of propofol and the development of pancreatitis [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .
In our study, hyperamylasaemia developed in some cases from the first day of propofol administration, while in others it occurred after nine full days of administration. It should be stated that prolonged use of propofol for sedation in the ICU has already been implicated in the development of acute pancreatitis 7,15 . Possidente et al described a patient who developed increased amylase and lipase concentrations after receiving high-dose propofol for nine days 15 .
Another important finding is that the increase in biological markers of pancreatitis after the initiation of propofol was followed by a decline of the markers after the treatment was stopped. This chronological consistency could indicate an aetiologic relationship between the infusion of propofol and pancreatitis 10 .
The causal mechanism of propofol-induced pancreatitis are unknown. The putative mechanism mainly suggested in the literature is a result of hypertriglyceridaemia, or defects in lipid metabolism, which can be summarised as follows. Hydrolysis of triglycerides in the pancreas leads to unbound fatty acids in high concentrations, which are toxic and can cause acinar cell and capillary injury. Furthermore, pancreatic capillaries are plugged by chylomicrons leading to ischaemia. The combination of an acidotic environment and free fatty acids causes activation of trypsinogen, initiating acute pancreatitis.
Whether transiently elevated triglyceride levels can lead to acute pancreatitis is an important question. It has been proposed that serum triglyceride concentrations should be monitored during prolonged infusions (>three days) because of the risk of hypertriglyceridaemia. The quantity of concomitant enteral or parenteral nutrition should be also considered. However, not all cases of propofol-associated pancreatitis can be explained by hypertriglyceridaemia, especially those occurring after a single bolus is used for the induction of anaesthesia.
Even though induction of hypertriglyceridaemia has been described as a putative mechanism, it seems unlikely that short-term administration of propofol could raise serum lipid levels as much as to induce pancreatitis 8, 20 . A published clinical trial focusing on pancreatic function in adult patients under postoperative sedation with propofol, found no elevated markers of altered pancreatic function 9 . Kumar et al reported a case of pancreatitis that occurred in a patient on propofol infusion and the episode was associated with hypertriglyceridaemia 10 . After the resolution of pancreatitis, the patient was inadvertently rechallenged with propofol and had a recurrence of pancreatitis, although this time no hypertriglyceridaemia was observed. This leads to the inference that propofol can cause pancreatitis by more than one mechanism, as has been suggested by Kesari et al 13 .
There are some limitations in our study, since the exact administered doses of propofol were not recorded. Also the lipid profile of the patients was not under daily surveillance.
Controlled studies involving large series are necessary to define the exact role of propofol in the development of pancreatitis. Our results can serve a hypothesis-generating function for the design of further studies. Meanwhile, given the extensive use of propofol and the potentially catastrophic implications of this complication, we feel that clinicians caring for patients in the ICU should be aware of this possible side-effect and that monitoring of amylase levels of propofol-sedated patients is warranted.
